Sclareol reduces CD4+CD25+Foxp3+T-reg cells in a breast cancer model in Vivo

Iranian Journal of Immunology

Volumn 10, Issue 1, 2013, Pages 10-21

  Noori, Shokoofe ^a   Hassan, Zuhair Mohammad ^b   Salehian, Omid ^c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c UNIVERSITY OF TEHRAN   (Iran)

Author keywords

IFN ; IL 4; Immunomodulator; Sclareol; T regulatory cell

Indexed keywords

CD4 ANTIGEN; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; SCLAREOL; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MODEL; CD4+ CD25+ FOXP3+ T REGULATORY CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG PURIFICATION; DRUG STRUCTURE; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; IN VIVO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; SALVIA; SALVIA SCLAREA; SPLEEN CELL; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD4; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CANCER VACCINES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DITERPENES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INJECTIONS, INTRAPERITONEAL; INTERFERON-GAMMA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-4; K562 CELLS; MICE; MICE, INBRED BALB C; SALVIA; T-LYMPHOCYTES, REGULATORY; TUMOR BURDEN;

EID: 84883227721     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hatziantoniou S, Dimas K, Georgopoulos A, Sotiriadou N, Demetzos C. Cytotoxic and antitumor activity of liposomeincorporated sclareol against cancer cell lines and human colon cancer xenografts. Pharmacol Res. 2006; 53:80-7.
2. Dimas K, Kokkinopoulos D, Demetzos C, Vaos B, Marselos M, Malamas M, et al. The effect of sclareol on growth and cell cycle progression of human leukemic cell lines. Leuk Res. 1999; 23:217-34.
3. Dimas K, Demetzos C, Vaos V, Ioannidis P, Trangas T. Trangas T Labdane type diterpenes down-regulate the expression of c-Myc protein but not of Bcl-2, in human leukemia T-cell lines undergoing apoptosis. Leuk Res. 2001; 25:449-54.
4. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science. 1997; 278:117-20.
5. Cherwinski HM, Schumacher JH, Brown KD, Mosmann TR. Two types of mouse helper T cell clone. III, Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J exp Med. 1987; 166:1229-44.
6. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clon. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986; 136:2348-62.
7. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989; 7:145-58.
8. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005; 6:345-52.
9. Mills KH, McGuirk P. Antigen-specific regulatory T cells--their induction and role in infection. Semin Immunol. 2004; 16:107-17.
10. Sakaguchi S. Naturally arising CD4+regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004; 22:531-62.
11. Vigouroux S, Yvon E, Biagi E, Brenner MK. Antigen-induced regulatory T cells. Blood. 2004; 104:26-33.
12. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10:942-9.
13. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, et al.0an cancer. Cancer Res. 2001; 61:4766-72.
14. Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, et al. Intratumor depletion of CD4cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med. 2005; 201:779-91.
15. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J Immunol. 1999; 163:5211-8.
16. Golgher D, Jones E, Powrie F, Elliott T, Gallimore A. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection ntigens. Eur J Immunol. 2002; 32:3267-75.
17. Noori S, Hassan ZM, Mohammadi M, Habibi Z, Sohrabi N, Bayanolhagh S. Sclareol modulates the Treg intra-tumoral infiltrated cell and inhibits tumor growth in vivo. Cellular Immunology. 2010; 263:148-53.
18. Hassan ZM, Yaraee R, Zare N, Ghazanfari T, Sarraf Nejad AH, Nazori B. Immunomodulatory affect of R10 fraction of garlic extract on natural killer activity. Int Immunopharmacol. 2003; 3:1483-9.
19. Kinghorn AD, Farnsworth NR, Soejarto DD, Cordell GA, Pezzuto JM, Udeani GO, et al. Novel strategies for the discovery of plant-derived anticancer agents. Pure Appl Chem. 1999; 71:1611-8.
20. Jung M, Ko I, Lee S, Choi SJ, Youn BH, Kim SK. A concise synthesis and in vitro cytotoxicity of new labdane diterpenes. Bioorg Med Chem Lett. 1998; 8:3295-8.
21. Dimas K, Demetzos C, Mitakou S, Vaos B, Marselos M, Tzavaras T, et al. Cytotoxic activity and antiproliferative effects of a new semi-synthetic derivative ent-3â-OH-manoyl oxide, on human leukemic cell lines. Anticancer Res. 1999; 19:4065-72.
22. Singh RP, Agarwal R. Natural flavonoids targeting deregulated cell cycle progression in cancer cells. Curr Drug Targets. 2006; 7:345-54.
23. D'Incalci M, Steward WP, Gescher AJ. Use of cancer chemopreventive phytochemicals as antineoplastic agents. Lancet Oncol. 2005; 6:899-904.
24. Nishino H, Murakoshi M, Mou XY, Wada S, Masuda M, Ohsaka Y, et al. Cancer prevention by phytochemicals. Oncology. 2005; 69:38-40.
25. Li WX, Cui CB, Cai B, Yaor XS. Labdane-type diterpenes as new cell cycle inhibitors and apoptosis inducers from Vitex trifolia L. J Asian Nat Prod Res. 2005; 7:95-105.
26. Dimas K, Papadaki M, Tsimplouli C, Hatziantoniou S, Alevizopoulos K, Pantazis P, Demetzos C. The proteome profile of two cell lines and their xenografts isolated from a patient with clear cell sarcoma (soft tissue melanoma). in vivo. Oncology 2009; 2323:63-8.
27. Hatziantoniou S, Dimas K, Georgopoulos A, Sotiriadou N, Demetzos C. Cytotoxic and antitumor activity of liposomeincorporated Sclareol against cancer cell lines and human colon cancer xenografts. Pharmacol Res. 2006; 53:80-7.
28. Noori S; Taghikhani M; Hassan ZM, Allameh A, Mostafaei A. Tehranolide could shift the immune response towards Th1 and modulate the intra-tumor infiltrated T regulatory cells. Iran J Immunol. 2009; 6:216-24.
29. Noori S, Taghikhani M, Hassan ZM, Allameha A, Mostafaei A. Tehranolide molecule modulates the immune response, reduces regulatory T cell and inhibits tumor growth in vivo. Mol. Immunol. 2010; 47:1579-84.
30. Langroudi L, Hassan ZM, Ebtekar M, Mahdavi M, Pakravan N, Noori S. A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model. Int Immunopharmacol. 2010; 10:1055-61.
31. Noori S, Hassan ZM. Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo. Cell Immunol. 2011; 271:67-72.
32. Farsam V, Hassan ZM, Zavaran-hosseini A, Noori S, Mahdavi M, Ranjbar M. Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo. Int Immunopharmacol. 2011; 11:1802-8.
33. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999; 31:28-33.